Glaukos Announces FDA Approval for Re-Administration of iDose® TR Glaukos Corporation, an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal…
WuXi Biologics and Sinorda Biomedicine Forge Strategic Partnership to Advance Development and Manufacturing of Innovative Bispecific Antibodies WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and…
BioNTech Appoints Kylie Jimenez as Chief People Officer to Management Board BioNTech SE announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer…
Biogen’s Litifilimab Earns FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus—First Targeted Therapy on the Horizon Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough…
This is the place for emergency medicine’ features real people working in emergency departments in Coventry and Manchester. Commissioned by the Royal College of Emergency Medicine (RCEM), the film is…
Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Phase 3 Trial for ATTRv-PN Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies,…
ICON’s Accellacare Site Network Enhances Oncology Research Through New Cancer Institute Partnership ICON plc today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the…
Will Forte Partners with Teva to Launch “Honestly HD”—A Candid Conversation About Huntington’s Disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced…
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible newly diagnosed multiple myeloma Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination…
Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890…
BioMarin Moves to Strengthen BalanceBioMarin Announces Proposed Private Offering of Senior Notes and New Senior Secured Term Loan Syndication BioMarin Pharmaceutical Inc. announced today that it intends to offer, subject…
WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc.…
